Fisetin is a plant flavonoid with strong anti-inflammatory, antioxidant, and senolytic properties, meaning it can help clear out damaged, aging cells that accumulate in your body over time. Found naturally in strawberries, apples, and persimmons, it has drawn serious research attention for its potential benefits across brain health, blood sugar regulation, skin aging, and chronic inflammation. Most evidence comes from animal and cell studies, with human clinical trials still underway, but the breadth of preclinical findings is notable.
Clearing Out Aging Cells
One of fisetin’s most talked-about properties is its ability to act as a senolytic, a compound that selectively kills senescent cells. These are cells that have stopped dividing but refuse to die. Instead of being cleared away by the immune system, they linger and release a cocktail of inflammatory signals that damage neighboring tissue and accelerate aging. This inflammatory output is known as the senescence-associated secretory phenotype, or SASP.
Fisetin targets these cells by blocking a survival pathway they depend on. Specifically, it inhibits a signaling chain that keeps senescent cells alive by preventing their natural self-destruct process. In studies on diabetic mice, chronic fisetin treatment reduced the burden of senescent cells in the aorta and suppressed the inflammatory signals those cells produce, resulting in measurably less vascular aging. A recent mouse study used an intermittent dosing approach (one week on, two weeks off, one week on) to clear excess senescent cells without disrupting the normal functions that healthy cellular aging supports. This intermittent protocol mirrors the approach being used in ongoing human trials.
Brain and Memory Protection
Fisetin has shown broad neuroprotective effects in preclinical research, with potential relevance to Alzheimer’s disease, Parkinson’s disease, vascular dementia, stroke recovery, and depression. In mice with chemically induced memory deficits, fisetin reversed the memory loss by activating a signaling pathway involved in forming new memories and boosting the brain’s internal antioxidant defenses.
At the cellular level, fisetin reduces neuroinflammation by quieting overactive immune cells in the brain. It also directly interferes with the formation of amyloid-beta fibrils, the protein clumps that are a hallmark of Alzheimer’s disease. These effects appear to stem from fisetin’s ability to simultaneously work through multiple molecular pathways: reducing oxidative stress, dampening inflammatory signaling, and supporting cell survival. No single mechanism explains its neuroprotective range, which is part of what makes it an active area of investigation.
Blood Sugar and Metabolic Health
Across more than a dozen animal studies, fisetin has shown consistent effects on blood sugar regulation and insulin sensitivity. In diabetic rats, it reduced blood glucose levels, improved insulin output, and suppressed the liver’s overproduction of glucose by dialing down the genes responsible for manufacturing it. In mice fed high-fat or high-fructose diets designed to mimic metabolic syndrome, fisetin improved insulin resistance, reduced liver damage, and corrected abnormal blood lipid levels.
The metabolic benefits extend beyond diabetes. In obese mice, fisetin protected against weight gain and glucose intolerance. In a rat model of polycystic ovary syndrome (PCOS), it normalized insulin resistance along with hormonal imbalances in testosterone, progesterone, and estradiol. In mice with non-alcoholic fatty liver disease, it lowered plasma insulin and glucose while improving a standard measure of insulin resistance. The common thread across these studies is fisetin’s ability to restore insulin signaling, particularly through a pathway that helps cells respond properly to insulin again.
Reducing Chronic Inflammation
Fisetin is a potent inhibitor of NF-kB, one of the master switches that turns on inflammatory gene expression throughout the body. In human airway cells, fisetin significantly reduced levels of a key inflammatory protein triggered by TNF-alpha, a cytokine involved in conditions ranging from arthritis to lung disease. It did this by blocking NF-kB’s activity and preventing the activation of the enzymes upstream of it. This mechanism has made researchers particularly interested in fisetin’s potential for inflammatory lung conditions like COPD.
Beyond the lungs, fisetin suppresses inflammatory enzymes (COX-2, iNOS) in brain immune cells and reduces the inflammatory output of senescent cells throughout the body. Because chronic low-grade inflammation underlies so many age-related diseases, this anti-inflammatory action is likely central to many of fisetin’s other observed benefits.
Skin Aging and UV Protection
When applied topically to hairless mice over 10 weeks, fisetin reduced wrinkle formation caused by UV exposure. Wrinkle scores dropped from 4.6 in UV-only mice to 2.7 in fisetin-treated mice. The compound also increased collagen content in the deeper skin layer (the dermis) and reduced skin redness caused by UV damage.
The mechanism involves blocking enzymes called matrix metalloproteinases (MMP-1 and MMP-2) that break down collagen after UV exposure. UV light triggers these enzymes, leading to the loss of structural support in skin. Fisetin suppressed their overexpression while also reducing the inflammatory response that drives further damage. It simultaneously activated a protective antioxidant pathway in skin cells, providing a dual defense against both the structural and oxidative components of sun damage.
Where Human Research Stands
Despite the volume of preclinical evidence, human clinical data on fisetin remains limited. The most prominent trial, called AFFIRM-LITE, is being conducted at the Mayo Clinic. It’s testing whether fisetin can reduce blood markers of inflammation and improve frailty in older adults. The trial is expected to report primary results by April 2026, with full completion estimated for 2027. Until those results arrive, the human evidence base for fisetin consists largely of its established safety profile and extrapolations from animal data.
Food Sources and Absorption Challenges
Strawberries are the richest dietary source of fisetin at 160 micrograms per gram, meaning a 100-gram serving (about seven medium strawberries) provides roughly 16 milligrams. Apples contain about 26.9 micrograms per gram, and persimmons about 10.5 micrograms per gram. Other sources include grapes, onions, and cucumbers, all at lower concentrations. For context, animal studies typically use doses that would translate to hundreds of milligrams in humans, far beyond what you could get from food alone.
Fisetin’s bioavailability is a significant limitation. Only about 44% of an oral dose reaches the bloodstream, largely because fisetin dissolves poorly in water and is rapidly broken down in the gut into metabolites. It’s absorbed quickly but also transformed quickly, which limits how much active fisetin reaches target tissues. Newer formulations designed to improve absorption, such as nanoemulsion-based delivery systems, have shown roughly 3.7-fold higher peak blood levels compared to plain fisetin powder in rat studies. Several supplement manufacturers now offer lipid-based or liposomal fisetin products aiming to address this gap, though human data comparing formulations is scarce.
Safety Considerations
Fisetin has a generally favorable safety profile in animal studies at moderate doses. Toxicity research on a fisetin-based compound in mice found no adverse effects on blood chemistry, organ tissue, or body weight at doses up to 200 mg/kg. At 400 mg/kg, however, significant problems emerged: liver enzyme elevations, kidney stress markers, inflammatory cell infiltration in multiple organs, and weight loss. This suggests a meaningful margin between effective and harmful doses, but also that more is not necessarily better.
Because fisetin influences several of the same pathways targeted by common medications, particularly those affecting blood sugar, inflammation, and blood clotting, there is theoretical potential for interactions with diabetes drugs, anti-inflammatory medications, and blood thinners. No systematic human interaction studies have been published. The intermittent dosing approach used in clinical trials (short bursts rather than continuous daily use) may partially mitigate accumulation-related risks, but this remains an area where caution is warranted.